Item 2.02 - Results of Operations and Financial Condition.
On April 7, 2022, AngioDynamics, Inc. ("AngioDynamics") issued a press release
announcing financial results for the fiscal third quarter ended February 28,
2022. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities under that Section. Furthermore, such information shall not be
deemed to be incorporated by reference into any filing under the Securities Act
of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall
be expressly set forth by specific reference in such a filing.
Item 7.01 - Regulation FD Disclosure.
Presentation slides discussing AngioDynamics and its fiscal third quarter ended
February 28, 2022 are furnished herewith as Exhibit 99.2.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K
(including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities under that Section.
Furthermore, the presentation slides shall not be deemed to be incorporated by
reference into any filing under the Securities Act or the Exchange Act.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics' expected future financial position, results of
operations, cash flows, business strategy, budgets, projected costs, capital
expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends," "anticipates,"
"plans," "believes," "seeks," "estimates," "project", "optimistic," or
variations of such words and similar expressions, are forward-looking
statements. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors are cautioned
that actual events or results may differ materially from AngioDynamics'
expectations, express or implied. Factors that may affect the actual results
achieved by AngioDynamics include, without limitation, the scale and scope of
the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by
competitors, infringement of AngioDynamics' technology or assertions that
AngioDynamics' technology infringes the technology of third parties, the ability
of AngioDynamics to effectively compete against competitors that have
substantially greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government regulations,
results of pending or future clinical trials, overall economic conditions
(including inflation, labor shortages
--------------------------------------------------------------------------------
and supply chain challenges including the cost and availability of raw
materials), the results of on-going litigation, challenges with respect to
third-party distributors or joint venture partners or collaborators, the results
of sales efforts, the effects of product recalls and product liability claims,
changes in key personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market conditions,
general market conditions, market acceptance, foreign currency exchange rate
fluctuations, the effects on pricing from group purchasing organizations and
competition, the ability of AngioDynamics to integrate acquired businesses, as
well as the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2021. AngioDynamics does not assume any obligation to publicly update or
revise any forward-looking statements for any reason.
--------------------------------------------------------------------------------
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated April 7, 2022.
99.2 Presentation, dated April 7, 2022.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses